The latest research regarding antidiabetic drugs has focused on dipeptidyl peptidase IV inhibitors that act by increasing the concentrations of the endogenous incretins GLP-1 and GI, and consequently reducing of fasting post-prandial hyperglycaemia [25]. This evidence concerns the gene GCG and Hyperglycemia.